The Current status of human cancer vaccines

Carol Kobrin, Larry W. Kwak

Research output: Contribution to journalArticle

Abstract

First generation cancer vaccines are being tested for clinical efficacy in the management of metastatic melanoma, colon cancer and non-Hodgkin's lymphoma. Expectations are that more patients will respond to this mode of therapy, and that responders will show longer periods of clinical remission if the potency of these various vaccines can be enhanced. This is being achieved by reformulating these vaccines to immunise the patient optimally for a cytotoxic T-cell and/or antibody response to the tumour-associated antigens. The prevailing strategy for improving the T-cell based vaccines has been to optimise tumour antigen presentation by the HLA molecules. Many of the vaccines designed primarily to elicit an antibody response are immunising against poorly immunogenic carbohydrate antigens. Therefore, increasing their potency through the use of various adjuvants and carrier molecules is being explored. This paper will report on nine therapeutic cancer vaccines currently in clinical trial for melanoma, colon cancer and non-Hodgkin's lymphoma. 1994

Original languageEnglish (US)
Pages (from-to)1241-1253
Number of pages13
JournalExpert Opinion on Investigational Drugs
Volume3
Issue number12
DOIs
StatePublished - Dec 1 1994
Externally publishedYes

Fingerprint

Cancer Vaccines
Vaccines
Neoplasm Antigens
Non-Hodgkin's Lymphoma
Colonic Neoplasms
Antibody Formation
Melanoma
Vaccine Potency
T-Lymphocytes
Antigen Presentation
Carbohydrates
Clinical Trials
Antigens
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The Current status of human cancer vaccines. / Kobrin, Carol; Kwak, Larry W.

In: Expert Opinion on Investigational Drugs, Vol. 3, No. 12, 01.12.1994, p. 1241-1253.

Research output: Contribution to journalArticle

Kobrin, Carol ; Kwak, Larry W. / The Current status of human cancer vaccines. In: Expert Opinion on Investigational Drugs. 1994 ; Vol. 3, No. 12. pp. 1241-1253.
@article{94971c7e07ba45f580ddcd69b10d7187,
title = "The Current status of human cancer vaccines",
abstract = "First generation cancer vaccines are being tested for clinical efficacy in the management of metastatic melanoma, colon cancer and non-Hodgkin's lymphoma. Expectations are that more patients will respond to this mode of therapy, and that responders will show longer periods of clinical remission if the potency of these various vaccines can be enhanced. This is being achieved by reformulating these vaccines to immunise the patient optimally for a cytotoxic T-cell and/or antibody response to the tumour-associated antigens. The prevailing strategy for improving the T-cell based vaccines has been to optimise tumour antigen presentation by the HLA molecules. Many of the vaccines designed primarily to elicit an antibody response are immunising against poorly immunogenic carbohydrate antigens. Therefore, increasing their potency through the use of various adjuvants and carrier molecules is being explored. This paper will report on nine therapeutic cancer vaccines currently in clinical trial for melanoma, colon cancer and non-Hodgkin's lymphoma. 1994",
author = "Carol Kobrin and Kwak, {Larry W.}",
year = "1994",
month = "12",
day = "1",
doi = "10.1517/13543784.3.12.1241",
language = "English (US)",
volume = "3",
pages = "1241--1253",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - The Current status of human cancer vaccines

AU - Kobrin, Carol

AU - Kwak, Larry W.

PY - 1994/12/1

Y1 - 1994/12/1

N2 - First generation cancer vaccines are being tested for clinical efficacy in the management of metastatic melanoma, colon cancer and non-Hodgkin's lymphoma. Expectations are that more patients will respond to this mode of therapy, and that responders will show longer periods of clinical remission if the potency of these various vaccines can be enhanced. This is being achieved by reformulating these vaccines to immunise the patient optimally for a cytotoxic T-cell and/or antibody response to the tumour-associated antigens. The prevailing strategy for improving the T-cell based vaccines has been to optimise tumour antigen presentation by the HLA molecules. Many of the vaccines designed primarily to elicit an antibody response are immunising against poorly immunogenic carbohydrate antigens. Therefore, increasing their potency through the use of various adjuvants and carrier molecules is being explored. This paper will report on nine therapeutic cancer vaccines currently in clinical trial for melanoma, colon cancer and non-Hodgkin's lymphoma. 1994

AB - First generation cancer vaccines are being tested for clinical efficacy in the management of metastatic melanoma, colon cancer and non-Hodgkin's lymphoma. Expectations are that more patients will respond to this mode of therapy, and that responders will show longer periods of clinical remission if the potency of these various vaccines can be enhanced. This is being achieved by reformulating these vaccines to immunise the patient optimally for a cytotoxic T-cell and/or antibody response to the tumour-associated antigens. The prevailing strategy for improving the T-cell based vaccines has been to optimise tumour antigen presentation by the HLA molecules. Many of the vaccines designed primarily to elicit an antibody response are immunising against poorly immunogenic carbohydrate antigens. Therefore, increasing their potency through the use of various adjuvants and carrier molecules is being explored. This paper will report on nine therapeutic cancer vaccines currently in clinical trial for melanoma, colon cancer and non-Hodgkin's lymphoma. 1994

UR - http://www.scopus.com/inward/record.url?scp=0028046077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028046077&partnerID=8YFLogxK

U2 - 10.1517/13543784.3.12.1241

DO - 10.1517/13543784.3.12.1241

M3 - Article

VL - 3

SP - 1241

EP - 1253

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 12

ER -